Analyzing Scienture (SCNX) & The Competition

Scienture (NASDAQ:SCNX) is one of 248 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its peers? We will compare Scienture to similar businesses based on the strength of its institutional ownership, profitability, risk, earnings, analyst recommendations, valuation and dividends.

Risk & Volatility

Scienture has a beta of 3.04, indicating that its stock price is 204% more volatile than the S&P 500. Comparatively, Scienture’s peers have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

5.7% of Scienture shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 21.4% of Scienture shares are owned by insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Scienture and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	0	0	1.00
Scienture Competitors	1951	3688	9724	395	2.54

As a group, “MED – DRUGS” companies have a potential upside of 74.67%. Given Scienture’s peers stronger consensus rating and higher possible upside, analysts plainly believe Scienture has less favorable growth aspects than its peers.

Profitability

This table compares Scienture and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	-10,364.22%	-24.47%	-19.30%
Scienture Competitors	-19,383.46%	-93.67%	-16.11%

Earnings & Valuation

This table compares Scienture and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scienture	$128,202.00	$9.07 million	-0.27
Scienture Competitors	$30.36 billion	$57.83 million	-0.27

Scienture’s peers have higher revenue and earnings than Scienture. Scienture is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Scienture peers beat Scienture on 8 of the 13 factors compared.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.